
Understanding clinical needs and the path to adoption is an important part of developing Archer’s Biochip platform.
Archer’s Head of Engineering, Dr Andrew Sexton, recently represented the company on the ANDHealth US delegation. Over three days in Palo Alto and San Francisco, the delegation explored the evidence, partnerships and commercial considerations needed to enter the US healthcare market.
The focus for Archer was understanding how to position its biosensor platform for US market entry: from clinical needs and market validation to partner expectations, reimbursement and how companies navigate the US healthcare payment landscape.
Visits to Amazon Health and One Medical, Google, Fogarty Innovation, UCSF Innovation Ventures and Stripe offered valuable perspectives on healthcare delivery, commercialisation and building a business in the US.
Panel discussions and Q&A with representatives from Kaiser Permanente Ventures, McKesson Ventures, Aphelion Capital and American Heart Association Ventures added insights into navigating early entry and positioning in the US healthcare market.
These conversations help sharpen the questions guiding the Biochip’s development:
The insights will help inform Archer’s development priorities as it works towards fast, accurate and accessible diagnostics.
Following the delegation, Andrew is continuing discussions about the biosensor platform and its potential role in more accessible, connected care at HLTH in Las Vegas.
Archer thanks ANDHealth for a well-run program, and the hosts, speakers and fellow delegates for sharing their experience and expertise. Thank you also to Investment NSW and the Australian Trade and Investment Commission (Austrade) for supporting this year’s delegation.
Get the latest updates on our breakthrough technologies and research developments. Join thousands of researchers, investors, and technology enthusiasts.